In answer to this need, the research team IVTD, builds on more than 30 years of experience in the development of in vitro liver models for pharmaco-toxicological and liver disease modelling purposes. IVTD’s proprietary hSKP-HPC (or HepaSTAR) model, is a novel in vitro model derived from human, post-natal skin stem cells proven in mechanistic investigations of chronic and acute liver injury caused by either drugs, chemicals or by disease.
HepaSTARs can be applied to:
- Hepatotoxicity screening and drug-induced liver injury (DILI) prediction
- In vitro non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) modelling and drug target discovery
- Interdisciplinary development of 3D/dynamic culture systems towards lab-on-chip applications